Ann: US HEPATITIS C PRESENTATION , page-11

Getting an oral presentation at AASLD is great news. It is the most prestigious of all the liver meetings. There will be some 8 to 10 thousand delegates including all the pharma players. Late breaking data from the second generation DDA's in Phase 2 & 3 studies will be presented.
TT-034 will not be competing against Telaprevir and Boceprevir as data from the European (EASL) and Asian (APASL) this year indicate the newer agents minus Pegylated Interferon and Ribavirin are showing 90-100% SVR (cure).
These 12 to 24 week oral regimes once daily, usually 2 agents combined eg. Sofosbuvir and Simeprevir with minimal side effects.
So let's hope that TT-034 can produce outstanding results as it faces stiff competition from the likes of Gilead, BMS and Janssen.